Your browser doesn't support javascript.
loading
Metalloproteinases and Hypertrophic Cardiomyopathy: A Systematic Review.
Serraino, Giuseppe Filiberto; Jiritano, Federica; Costa, Davide; Ielapi, Nicola; Napolitano, Desirèe; Mastroroberto, Pasquale; Bracale, Umberto Marcello; Andreucci, Michele; Serra, Raffaele.
Affiliation
  • Serraino GF; Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
  • Jiritano F; Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
  • Costa D; Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.
  • Ielapi N; Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.
  • Napolitano D; Department of Public Health and Infectious Disease, "Sapienza" University of Rome, 00185 Roma, Italy.
  • Mastroroberto P; Ph.D. Student "Digital Medicine" Ph.D. Programm-Magna Graecia, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
  • Bracale UM; Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
  • Andreucci M; Department of Public Health, Vascular Surgery Unit, University of Naples "Federico II", 80126 Naples, Italy.
  • Serra R; Department of Health Sciences, Nephrology Unit, University of Catanzaro, 88100 Catanzaro, Italy.
Biomolecules ; 13(4)2023 04 11.
Article in En | MEDLINE | ID: mdl-37189412
ABSTRACT
Hypertrophic cardiomyopathy (HCM) is a genetic condition determined by an altered collagen turnover of the extracellular matrix. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are abnormally released in patients with HCM. The purpose of this systematic review was to thoroughly summarize and discuss the existing knowledge of MMPs profile in patients with HCM. All studies meeting the inclusion criteria (detailed data regarding MMPs in patients with HCM) were selected, after screening the literature from July 1975 to November 2022. Sixteen trials that enrolled a total of 892 participants were included. MMPs-particularly MMP2-levels were found higher in HCM patients compared to healthy subjects. MMPs were used as biomarkers after surgical and percutaneous treatments. Understanding the molecular processes that control the cardiac ECM's collagen turnover allows for a non-invasive evaluation of HCM patients through the monitoring of MMPs and TIMPs.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Hypertrophic Type of study: Systematic_reviews Limits: Humans Language: En Journal: Biomolecules Year: 2023 Document type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Hypertrophic Type of study: Systematic_reviews Limits: Humans Language: En Journal: Biomolecules Year: 2023 Document type: Article Affiliation country: Italy